Goldman Sachs Group Inc I Teos Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 913,013 shares of ITOS stock, worth $6.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
913,013
Previous 732,272 24.68%
Holding current value
$6.63 Million
Previous $10.9 Million 14.22%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$10.09 - $17.97 $1.82 Million - $3.25 Million
180,741 Added 24.68%
913,013 $9.32 Million
Q2 2024

Aug 13, 2024
BUY
$10.33 - $18.09 $165,434 - $289,711
16,015 Added 2.24%
732,272 $10.9 Million
Q1 2024

May 15, 2024
SELL
$9.89 - $13.64 $255,270 - $352,062
-25,811 Reduced 3.48%
716,257 $9.77 Million
Q4 2023

Feb 13, 2024
BUY
$8.57 - $11.06 $1.14 Million - $1.47 Million
132,856 Added 21.81%
742,068 $8.13 Million
Q3 2023

May 14, 2024
SELL
$10.95 - $14.6 $1.45 Million - $1.94 Million
-132,856 Reduced 17.9%
609,212 $6.67 Million
Q3 2023

Nov 14, 2023
SELL
$10.95 - $14.6 $377,260 - $503,013
-34,453 Reduced 5.35%
609,212 $6.67 Million
Q2 2023

May 14, 2024
BUY
$12.93 - $18.05 $2.66 Million - $3.71 Million
205,556 Added 46.92%
643,665 $8.52 Million
Q2 2023

Aug 14, 2023
BUY
$12.93 - $18.05 $2.66 Million - $3.71 Million
205,556 Added 46.92%
643,665 $8.52 Million
Q1 2023

May 14, 2024
BUY
$13.02 - $22.62 $151,005 - $262,346
11,598 Added 2.72%
438,109 $5.96 Million
Q1 2023

May 11, 2023
BUY
$13.02 - $22.62 $151,005 - $262,346
11,598 Added 2.72%
438,109 $5.96 Million
Q4 2022

May 14, 2024
BUY
$17.77 - $21.6 $1.47 Million - $1.79 Million
82,910 Added 24.13%
426,511 $8.33 Million
Q4 2022

Feb 13, 2023
BUY
$17.77 - $21.6 $1.47 Million - $1.79 Million
82,910 Added 24.13%
426,511 $8.33 Million
Q3 2022

May 14, 2024
SELL
$18.6 - $27.25 $1.25 Million - $1.84 Million
-67,470 Reduced 16.41%
343,601 $6.55 Million
Q3 2022

Nov 10, 2022
SELL
$18.6 - $27.25 $1.25 Million - $1.84 Million
-67,470 Reduced 16.41%
343,601 $0
Q2 2022

May 14, 2024
SELL
$16.57 - $35.1 $5.48 Million - $11.6 Million
-330,997 Reduced 44.6%
411,071 $8.47 Million
Q2 2022

Aug 15, 2022
BUY
$16.57 - $35.1 $3.78 Million - $8 Million
227,930 Added 124.46%
411,071 $8.47 Million
Q1 2022

May 16, 2022
BUY
$31.92 - $47.45 $2.1 Million - $3.12 Million
65,837 Added 56.13%
183,141 $5.89 Million
Q4 2021

Feb 14, 2022
SELL
$26.23 - $47.86 $1.52 Million - $2.77 Million
-57,980 Reduced 33.08%
117,304 $5.46 Million
Q3 2021

Nov 10, 2021
BUY
$23.91 - $29.58 $4.19 Million - $5.18 Million
175,284 New
175,284 $4.73 Million

Others Institutions Holding ITOS

# of Institutions
166
Shares Held
36.6M
Call Options Held
1.95M
Put Options Held
374K
View Full List

About iTeos Therapeutics, Inc.

ITOS Quotes by TradingView
  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $258M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email